Dongrui R. Lu
- Oncology top 0.5%
- HER2/EGFR in Cancer Research 21
- Cancer-related Molecular Pathways 20
- Cancer Treatment and Pharmacology 7
- Lung Cancer Research Studies 7
- Pulmonary and Respiratory Medicine top 0.5%
- Advanced Breast Cancer Therapies 45
- Renal cell carcinoma treatment 6
- Cancer Research top 1%
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research 9
- Neurology top 1%
-
- Neuroendocrine Tumor Research Advances 6
- Co-authors
- Richard S. FinnKaren A. GelmonHope S. RugoVéronique DièrasEric GauthierNadia HarbeckDennis J. SlamonMiguel Martín
- Journals
- New England Journal of Medicine (2 papers)Journal of Clinical Oncology (13 papers)JNCI Journal of the National Cancer Institute (3 papers)
- Partner nations
- United StatesItalyCanada
In The Last Decade
Dongrui R. Lu
65 papers receiving 6.0k citations
Hit Papers
Peers
Comparison fields: 5 of 98
- Oncology 4.4k
- Pulmonary and Respiratory Medicine 3.7k
- Cancer Research 1.5k
- Genetics 806
- Neurology 1.1k
Countries citing papers authored by Dongrui R. Lu
This map shows the geographic impact of Dongrui R. Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dongrui R. Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dongrui R. Lu more than expected).
Fields of papers citing papers by Dongrui R. Lu
This network shows the impact of papers produced by Dongrui R. Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dongrui R. Lu. The network helps show where Dongrui R. Lu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Dongrui R. Lu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 2 | |
| 4 | 2024 | 0 | |
| 5 | 2024 | 3 | |
| 6 | 2021 | 40 | |
| 7 | 2020 | 25 | |
| 8 | Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-upbreakdown → | 2019 | 286 |
| 9 | 2019 | 24 | |
| 10 | 2018 | 67 | |
| 11 | 2017 | 6 | |
| 12 | 2017 | 2 | |
| 13 | 2017 | 2 | |
| 14 | 2016 | 46 | |
| 15 | 2016 | 5 | |
| 16 | 2016 | 6 | |
| 17 | Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) and Updated Overall Survival (OS) of Sunitinib versus Placebo for Patients with Progressive, Unresectable, Well Differentiated Pancreatic Neuroendocrine Tumor (NET) | 2012 | 4 |
| 18 | Pharmacokinetics, tissue distribution and excretion of Vitexin in mice | 2012 | 2 |
| 19 | Evaluation of Progression-Free Survival by Blinded Independent Central Review in Patients With Progressive, Well-Differentiated Pancreatic Neuroendocrine Tumors Treated With Sunitinib or Placebo | 2011 | 2 |
| 20 | Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinibbreakdown → | 2011 | 446 |
About Dongrui R. Lu
Dongrui R. Lu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics, having authored 72 papers that have together received 6.1k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (45 papers), HER2/EGFR in Cancer Research (21 papers), Cancer-related Molecular Pathways (20 papers), Chronic Lymphocytic Leukemia Research (9 papers), Cancer Treatment and Pharmacology (7 papers), Lung Cancer Research Studies (7 papers), Renal cell carcinoma treatment (6 papers) and Neuroendocrine Tumor Research Advances (6 papers). The work is most often cited by research in Oncology (4.4k citations), Pulmonary and Respiratory Medicine (3.7k citations) and Cancer Research (1.5k citations). Dongrui R. Lu has collaborated with scholars based in United States, Italy and Canada. Frequent co-authors include Richard S. Finn, Karen A. Gelmon, Hope S. Rugo, Véronique Dièras, Eric Gauthier, Nadia Harbeck, Dennis J. Slamon, Miguel Martín, Oleg Lipatov and Janice M. Walshe. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.